DPP-4 inhibition has beneficial effects on the heart after myocardial infarction

J Mol Cell Cardiol. 2016 Feb:91:72-80. doi: 10.1016/j.yjmcc.2015.12.026. Epub 2015 Dec 29.

Abstract

Aims: Dipeptidyl peptidase-4 (DPP-4) inhibitors are reported to have protective effects on various cells but it is unclear how DPP-4 inhibitors have cardioprotective effects. Our aim was to study the mechanisms of cardioprotective effects by DPP-4 inhibition.

Methods and results: C57BL/6 mice and DPP-4 knockout (DPP-4KO) mice were subjected to left coronary artery ligation to produce acute myocardial infarction (MI). C57BL/6 mice were then treated with vehicle or DPP-4 inhibitor. Left ventricular function, infarct size, the number of vessels, and myocardial ischemia were assessed at 5days after MI. The treatment with DPP-4 inhibitor significantly improved cardiac function and decreased the infarct size. DPP-4 inhibitor increased the ratio of endothelial cell numbers to a cardiomyocyte. The extent of myocardial ischemia and the number of TUNEL-positive cells in the border area were significantly decreased by DPP-4 inhibitor. Stromal cell-derived factor-1α (SDF-1α) level in myocardium was significantly increased by DPP-4 inhibitor. Those cardioprotective effects after MI were also recognized in DPP-4KO mice. DPP-4 protein was expressed on rat neonatal cardiomyocytes and DPP-4 inhibitor significantly reduced hypoxia-induced apoptosis in the cardiomyocytes. However, this effect was abolished by the pretreatment with a CXCR4 antagonist or a signal transducer and activator of transcription 3 (STAT3) inhibitor. The beneficial effects of DPP-4 inhibitor on heart failure after MI were abolished by cardiomyocyte-specific deletion of STAT3.

Conclusions: DPP-4 inhibition may have direct protective effects on the post-MI heart by inducing an antiapoptotic effect and inhibiting a decrease in vessel number through the SDF-1α/CXCR4-mediated STAT3 signaling pathway.

Keywords: Apoptosis; DPP-4; Heart failure; Myocardial infarction; STAT3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Apoptosis / drug effects
  • Cardiotonic Agents / pharmacology
  • Chemokine CXCL12 / agonists
  • Chemokine CXCL12 / genetics*
  • Chemokine CXCL12 / metabolism
  • Dipeptidyl Peptidase 4 / deficiency
  • Dipeptidyl Peptidase 4 / genetics*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Disease Models, Animal
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Female
  • Gene Expression Regulation
  • Heart Failure / genetics
  • Heart Failure / metabolism
  • Heart Failure / pathology
  • Heart Failure / prevention & control*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / genetics
  • Myocardial Infarction / metabolism
  • Myocardial Infarction / pathology
  • Myocardium / metabolism
  • Myocardium / pathology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Receptors, CXCR4 / antagonists & inhibitors
  • Receptors, CXCR4 / genetics*
  • Receptors, CXCR4 / metabolism
  • STAT3 Transcription Factor / antagonists & inhibitors
  • STAT3 Transcription Factor / genetics*
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction
  • Ventricular Function, Left / drug effects

Substances

  • CXCR4 protein, mouse
  • Cardiotonic Agents
  • Chemokine CXCL12
  • Dipeptidyl-Peptidase IV Inhibitors
  • Receptors, CXCR4
  • STAT3 Transcription Factor
  • Stat3 protein, mouse
  • Dipeptidyl Peptidase 4